

## Data Sharing Statement

Martin. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-Risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. *JAMA Oncol*. Published June 02, 2022. doi:10.1001/jamaoncol.2022.1488

### Data

**Data available:** No

### Additional Information

**Explanation for why data not available:** Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request six months after the indication studied has been approved in the US and EU or after primary publication acceptance, whichever is later. No expiration date for data requests is set once the data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the online instructions.